Access Pharmaceuticals Inc. focuses its efforts on developing and commercializing proprietary products for the treatment and supportive care of cancer patients. The company’s products include ProLindac™, which is currently in phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis.
The company today announced highlights from a poster presentation of MuGard at this year’s European Society of Medical Oncology Conference in Milan, Italy. Access CEO Jeffery Davis said the results reflect MuGuard as a valuable therapeutic option for the treatment and prevention of oral mucositis (OM), a side effect of raio/chemotherapy.
“These additional findings out of Europe are very exciting and strengthen our belief in the clinical benefits that MuGard can provide patients undergoing radiation and chemotherapy,” Davis stated in the press release. “This data confirms the competitive advantages of MuGard over the current treatment options on the market and we will use this data to educate patients, clinicians and the medical industry on the superior attributes of our product.”
The presentation noted MuGuard’s clinical experience, including:
• MuGard’s ability to provide significant improvement and/or stabilization of oral mucositis lesions and symptoms of oral mucositis (OM) in more than 75% of cancer patients treated with radiotherapy/chemotherapy;
• A 52 percent reduction in oral discomfort (oral pain and swallowing ability) in patients with pre-existing lesions of OM, and reported a substantial reduction in the use of pain medication;
• MuGard’s ready-to-use formulation was well accepted by 86 percent of patients involved in this assessment program;
• No MuGard-related adverse reactions were identified in the clinical practice.
Earlier this year, Access Pharmacueticals presented its MuGard data and clinical experience at the Multinational Association of Supportive Care in Cancer (MASSC Conference), showcasing data from a clinical trial for treatment of head and neck cancer with positive results of MuGard for oral mucositis prevention.
For more information visit www.accesspharma.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment